BioSpace News Archive

Drug Development

Following Phase II Failure, Ironwood and AbbVie Halt Development of Delayed-Release Linzess

Ironwood and AbbVie said a Phase II trial assessing the drug candidate MD-7246, a delayed-release formulation of Linzess, did not meet its primary or key secondary endpoints.

May 29, 2020
·
2 min read
·
Alex Keown
Business

In the Fight Against COVID-19, These Female Scientists Are Breaking Ground

The San Francisco Business Times recently highlighted four women who are making strides in addressing the novel coronavirus in its “Influential Women of 2020” series.

May 29, 2020
·
3 min read
·
Alex Keown
BioForest

Clinical Catch-Up: May 25-29

In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.

May 29, 2020
·
10 min read
·
Mark Terry
FDA

FDA Approves Lilly’s Tauvid Imaging Agent to Help Diagnose Alzheimer’s Disease

Tauvid is the first and only approved diagnostic agent for imaging tau neurofibrillary tangles (NFTs) in the brain.

May 29, 2020
·
3 min read
·
Mark Terry
Policy

FDA Action Alert: Foamix, Immunomedics and Merck

Although the U.S. FDA is very busy dealing with emergency use approvals for diagnostics and possible treatments for COVID-19, it is still evaluating and approving therapies for non-COVID-19 indications. Here’s a look at this week’s calendar.

May 29, 2020
·
4 min read
·
Mark Terry
Drug Development

AstraZeneca’s Tagrisso Improved Disease-Free Survival in NSCLC with EGFR Mutations by 89%

The company is presenting the study of Tagrisso during the plenary session of the American Society of Clinical Oncology ASCO20 Virtual Scientific Program on Sunday, May 31.

May 29, 2020
·
3 min read
·
Mark Terry
Business

Ipsen Taps Sanofi Vaccines Head David Loew as New CEO

After four years as head of Sanofi’s vaccines division, David Loew is departing the pharma giant to take on a new role – chief executive officer of Paris-based Ipsen, effective July 1.

May 29, 2020
·
2 min read
·
Alex Keown
Drug Development

Ziopharm Phase I Trial Yields Positive Results for Treatment of rGBM

The main Phase I monotherapy study had a favorable safety profile, showing that Ad+V was safely administered and tolerably in both craniotomy and stereotactic subjects.

May 29, 2020
·
3 min read
·
Krystle Vermes
Drug Development

Allogene’s ALLO-501 Shows Positive Results in Its Phase I ALPHA Trial

The data, which was presented at the American Society of Clinical Oncology annual meeting, looked into the use of ALLO-501 for relapsed/refractory non-Hodgkin lymphoma.

May 29, 2020
·
3 min read
·
Krystle Vermes
Deals

Endo International plc Announces Early Tender Results Of Its Previously Announced Exchange Offers And Consent Solicitations

Endo International plc (the “Company”) (NASDAQ: ENDP) announced today the early tender results of the previously announced Exchange Offers and Consent Solicitations (each as defined below) by wholly owned subsidiaries Pa

May 29, 2020
·
11 min read